Scynexis

Scynexis, Inc. is a biotechnology company based in Jersey City, New Jersey, primarily focused on developing innovative therapies for fungal infections. Its lead product candidate, ibrexafungerp, is an oral and intravenous drug designed to treat various fungal infections, such as vulvovaginal candidiasis, invasive candidiasis, and invasive aspergillosis. Ibrexafungerp is a unique triterpenoid glucan synthase inhibitor that demonstrates efficacy against a wide range of Candida and Aspergillus species, including resistant strains. The company has successfully completed Phase 2 clinical trials for ibrexafungerp and collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC for its development and commercialization. Scynexis also engages in broader drug discovery and development projects, including antibacterials and antivirals, and offers contract research services in areas such as medicinal chemistry and bioanalysis. Founded in 1999, Scynexis was initially known as SCYNEXIS Chemistry & Automation, Inc. before rebranding in 2002.